Cagrilintide
INVESTIGATIONALLong-acting amylin analog
Also known as: AM833, CagriSema (with semaglutide)
Investigational. Not FDA approved. Studied alone and combined with semaglutide (CagriSema), which is under regulatory review.
A real evidence base, with gaps
- Regulatory standing. In clinical trials, not yet approved
- Limited human data. Some human data exists, not conclusive
- Registered human trials. 43 registered studies on ClinicalTrials.gov, most advanced Phase 3
- 1 cited source. Cited references provided
A read on the weight of evidence and regulatory standing behind this compound. It is not a safety score, not a purity or quality rating, and not medical advice. It is not a claim that this compound treats, cures, or prevents any condition, and not an endorsement or a recommendation to buy or use it. A low score means the evidence is thin — not that a product is unsafe; a high score means the evidence is strong — not that anyone should take it. PLOBT is independent and takes no money from any vendor; no company can pay to change this score.
Proven so far: in trials, cagrilintide plus semaglutide (CagriSema) produced some of the largest weight loss seen for a GLP-1-based therapy. NOT yet approved. Standalone benefit and long-term safety are still being established.
What it is
Mimics amylin, a hormone that promotes satiety, complementing GLP-1 mechanisms.
What the research says
CagriSema led to large average weight loss in trials, among the highest reported for GLP-1-based drugs. Under FDA review with potential 2026 approval.
Published literature
Live from Europe PMC. Peer-reviewed papers discussing Cagrilintide in their title or abstract, most-cited first. This is how much has been published — not how much is proven in humans. It counts landmark trials, animal studies and reviews alike.
Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.
Registered human trials
Live from ClinicalTrials.gov, the US NIH registry of human studies, refreshed daily. Counts studies where Cagrilintide is the intervention being tested.
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
A Study of How CagriSema Works on Appetite in People With Excess Body Weight
A Study on How NNC0174-1213 Works in People With Overweight or Obesity.
Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease
FDA recalls & enforcement
Cagrilintide has no FDA recall or drug record at all — because it is not an FDA-regulated drug. That absence is not a safety signal. It means this compound is sold outside the system that inspects, tracks and recalls unsafe products in the first place.
Source: openFDA drug enforcement.
What people log it for
Descriptive, based on what users track. Not an endorsement or a suggested use.
Risks & unknowns
- Not approved: long-term safety still being established.
- GI side effects reported in trials.
- No verified consumer supply exists yet.
Doses reported in studies & protocols
Trial doses only. There is no approved dose. This is not a recommendation.
Purity reality
No legitimate consumer supply. Treat gray-market product as unverified.
None yet. PLOBT does not publish invented purity numbers. Real third-party COA data, mapped to vendor and batch, is in development — and it is the one thing we refuse to fake.
Sources
We cite peer-reviewed journals, PubMed/PMC, FDA and university sources, not vendor marketing.